Form 8-K - Current report:
SEC Accession No. 0001193125-24-215909
Filing Date
2024-09-09
Accepted
2024-09-09 16:15:53
Documents
19
Period of Report
2024-09-05
Items
Item 1.03: Bankruptcy or Receivership
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d887098d8k.htm   iXBRL 8-K 39550
2 EX-2.1 d887098dex21.htm EX-2.1 419192
3 EX-99.1 d887098dex991.htm EX-99.1 686067
7 GRAPHIC g887098page63.jpg GRAPHIC 7646
8 GRAPHIC g887098page63a.jpg GRAPHIC 7287
9 GRAPHIC g887098page63b.jpg GRAPHIC 6927
10 GRAPHIC g887098page63c.jpg GRAPHIC 9827
  Complete submission text file 0001193125-24-215909.txt   1515604

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eigrq-20240905.xsd EX-101.SCH 2514
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigrq-20240905_lab.xml EX-101.LAB 17956
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigrq-20240905_pre.xml EX-101.PRE 11239
22 EXTRACTED XBRL INSTANCE DOCUMENT d887098d8k_htm.xml XML 3779
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

EIN.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 241287448
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)